- Home
- PRO vs PHAR Comparison
PRO vs PHAR Comparison
Compare PRO & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRO
- PHAR
- Stock Information
- Founded
- PRO 1985
- PHAR 1988
- Country
- PRO United States
- PHAR Netherlands
- Employees
- PRO N/A
- PHAR N/A
- Industry
- PRO EDP Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- PRO Technology
- PHAR Health Care
- Exchange
- PRO Nasdaq
- PHAR Nasdaq
- Market Cap
- PRO 863.3M
- PHAR 731.1M
- IPO Year
- PRO 2007
- PHAR N/A
- Fundamental
- Price
- PRO $16.52
- PHAR $10.39
- Analyst Decision
- PRO Strong Buy
- PHAR Strong Buy
- Analyst Count
- PRO 10
- PHAR 3
- Target Price
- PRO $28.10
- PHAR $30.00
- AVG Volume (30 Days)
- PRO 1.2M
- PHAR 3.7K
- Earning Date
- PRO 07-29-2025
- PHAR 07-31-2025
- Dividend Yield
- PRO N/A
- PHAR N/A
- EPS Growth
- PRO N/A
- PHAR N/A
- EPS
- PRO N/A
- PHAR N/A
- Revenue
- PRO $336,006,000.00
- PHAR $320,708,000.00
- Revenue This Year
- PRO $10.25
- PHAR $13.31
- Revenue Next Year
- PRO $10.46
- PHAR $7.68
- P/E Ratio
- PRO N/A
- PHAR N/A
- Revenue Growth
- PRO 7.97
- PHAR 24.13
- 52 Week Low
- PRO $13.61
- PHAR $6.65
- 52 Week High
- PRO $29.84
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- PRO 52.43
- PHAR 47.23
- Support Level
- PRO $14.76
- PHAR $9.88
- Resistance Level
- PRO $20.28
- PHAR $10.59
- Average True Range (ATR)
- PRO 0.61
- PHAR 0.31
- MACD
- PRO 0.23
- PHAR -0.12
- Stochastic Oscillator
- PRO 96.58
- PHAR 31.68
About PRO PROS Holdings Inc.
Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.